297 related articles for article (PubMed ID: 15860163)
21. Excessive pricing in the pharmaceutical industry: adding another string to the bow of EU competition law.
Danieli D
Health Econ Policy Law; 2021 Jan; 16(1):64-75. PubMed ID: 32434612
[TBL] [Abstract][Full Text] [Related]
22. New prescription for the Spanish drug sector: fighting against public deficit without wasting ammunition.
Antoñanzas F; Gómez P
Pharmacoeconomics; 2010; 28(11):977-80. PubMed ID: 20936881
[No Abstract] [Full Text] [Related]
23. Looking inward: regional parallel trade as a means of bringing affordable drugs to Africa.
Buckely M
Seton Hall Law Rev; 2011; 41(2):625-69. PubMed ID: 21739760
[No Abstract] [Full Text] [Related]
24. Comparative approaches to pharmaceutical price regulation in the European Union.
Mrazek MF
Croat Med J; 2002 Aug; 43(4):453-61. PubMed ID: 12187524
[TBL] [Abstract][Full Text] [Related]
25. Australian drugs scheme threatens free-trade talks.
Fickling D
Lancet; 2004 Jan; 363(9405):299. PubMed ID: 14753208
[No Abstract] [Full Text] [Related]
26. The UK pharmaceutical market. An overview.
Towse A
Pharmacoeconomics; 1996; 10 Suppl 2():14-25. PubMed ID: 10163432
[TBL] [Abstract][Full Text] [Related]
27. [An analysis of the pharmaceuticals market in Vietnam].
Simonet D
Sante; 2001; 11(3):155-60. PubMed ID: 11641078
[TBL] [Abstract][Full Text] [Related]
28. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
ESMO Open; 2019; 4(6):e000550. PubMed ID: 31798977
[TBL] [Abstract][Full Text] [Related]
29. The role of bioethics in the international prescription drug market: economics and global justice.
Newland SE
Penn Bioeth J; 2006; 2(2):8-12. PubMed ID: 17146900
[TBL] [Abstract][Full Text] [Related]
30. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
31. Challenges to achieving value in drug spending in a decentralized country: the Spanish case.
Antoñanzas F
Value Health; 2003; 6 Suppl 1():S52-63. PubMed ID: 12846926
[TBL] [Abstract][Full Text] [Related]
32. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
[TBL] [Abstract][Full Text] [Related]
33. [Impact Reimbursement Act on the pharmaceutical market in Poland].
Giermaziak W
Pol Merkur Lekarski; 2014 Apr; 36(214):270-3. PubMed ID: 24868902
[TBL] [Abstract][Full Text] [Related]
34. Global "hold-em".
Cassidy BS
Geriatr Nurs; 2006; 27(1):21-3. PubMed ID: 16483897
[No Abstract] [Full Text] [Related]
35. Differential pricing of new pharmaceuticals in lower income European countries.
Kaló Z; Annemans L; Garrison LP
Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
[TBL] [Abstract][Full Text] [Related]
36. Is parallel trade in medicines compatible with the single European market?
Senior I
Pharmacoeconomics; 1992; 1(Suppl 1):70-6. PubMed ID: 10172047
[TBL] [Abstract][Full Text] [Related]
37. Pharmaceutical Manufacturing in the EU and the EU-US Mutual Recognition Agreement.
Gaspar Ernesto LM; Dias Loureiro RM
PDA J Pharm Sci Technol; 2020; 74(6):617-626. PubMed ID: 32540862
[TBL] [Abstract][Full Text] [Related]
38. Norway's pivotal role in regulatory health economics and pharmaceutical cost containment--what can other countries learn?
Andersson F
Health Policy; 1992 May; 21(1):17-34. PubMed ID: 10171032
[TBL] [Abstract][Full Text] [Related]
39. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
Apel BT
Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
[TBL] [Abstract][Full Text] [Related]
40. Pharma Pricing & Market Access Europe 2016--Health Network Communications' Tenth Annual Conference (February 23-25, 2016--London, UK).
D'Souza P
Drugs Today (Barc); 2016 Mar; 52(3):203-6. PubMed ID: 27186595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
